Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...
Please provide your email address to receive an email when new articles are posted on . A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
Please provide your email address to receive an email when new articles are posted on . DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV ...
The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM) Bortezomib (Bz) is a novel proteasome ...
RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients. Background: To date convincing clinical success with oncolytic ...
Subcutaneous nivolumab injection marks a significant advancement in cancer therapy, offering faster administration than traditional intravenous methods. The shift to subcutaneous delivery could lead ...
The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...
The probability of spontaneous conversion to sinus rhythm (SVC) was increased with the intravenous administration of magnesium and potassium in patients with nonpermanent atrial fibrillation ...
The U.S. Food and Drug Administration (FDA) has approved the first medication delivered intravenously to reduce both episodic and chronic migraine. The FDA gave the go-ahead based on research showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results